Equities researchers at StockNews.com initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a research note issued on Sunday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 0.24. Genocea Biosciences has a 12 month low of $0.00 and a 12 month high of $0.00. The company has a market capitalization of $6,000.00, a P/E ratio of 0.00 and a beta of 1.61.
Genocea Biosciences Company Profile
Read More
- Five stocks we like better than Genocea Biosciences
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- Industrial Products Stocks Investing
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- Why Are Stock Sectors Important to Successful Investing?
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.